title: Rotavirus vaccines: targeting the developing world.
abstract: For the past 2 decades, rotavirus infection, the most common cause of severe diarrhea in children, has been a priority target for vaccine development. This decision to develop rotavirus vaccines is predicated on the great burden associated with fatal rotavirus disease (i.e., 440,000 deaths/year), the firm scientific basis for developing live oral vaccines, the belief that increased investment in development at this time could speed the introduction of vaccines in developing countries, and the appreciation that implementation of a vaccine program should result in a measurable decrease in the number of hospitalizations and deaths associated with rotavirus disease within 2-3 years. RotaShield (Wyeth-Ayerst), the first rotavirus vaccine licensed in the United States, was withdrawn after 9 months because of a rare association of the vaccine with the development of intussusception. In the developing world, this vaccine could still have had a measurable effect, because the benefits of preventing deaths due to rotavirus disease would have been substantially greater than the rare risk of intussusception. Two live oral vaccines being prepared by GlaxoSmithKline and Merck have completed large-scale clinical trials. The GlaxoSmithKline vaccine has been licensed in Mexico and the Dominican Republic, and the Merck vaccine could be licensed in the United States within 1 year; several other candidate vaccines are in earlier stages of testing. However, many challenges remain before any of these vaccines can be incorporated into childhood immunization programs in the developing world. First, vaccine efficacy, which has already been demonstrated in children in industrialized and middle-income countries, needs to be proven in poor developing countries in Africa and Asia. The safety of vaccines with regard to the associated risk of intussusception must be demonstrated as well. Novel financing strategies will be needed to ensure that new vaccines are affordable and available in the developing world. Decision makers and parents in developing countries need to know about this disease that has little name recognition and is rarely diagnosed. Finally, for the global effort toward the prevention of rotavirus disease to be successful, special efforts will be required in India, China, and Indonesia, because one-third of all deaths due to rotavirus disease occur in these countries, and because these countries depend almost entirely on vaccines manufactured domestically.
authors.affiliation: Viral Gastroenteritis Section, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA. rglass@cdc.gov
authors.forename: Roger I
authors.initials: RI
authors.lastname: Glass
authors.forename: Joseph S
authors.initials: JS
authors.lastname: Bresee
authors.forename: Reina
authors.initials: R
authors.lastname: Turcios
authors.forename: Thea K
authors.initials: TK
authors.lastname: Fischer
authors.forename: Umesh D
authors.initials: UD
authors.lastname: Parashar
authors.forename: A Duncan
authors.initials: AD
authors.lastname: Steele
mesh_terms: D000284:Administration, Oral; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D003365:Costs and Cost Analysis; D003906:Developing Countries; D003967:Diarrhea / Q000453:epidemiology / Q000517:prevention & control; D005838:Genotype; D014943:Global Health; D006801:Humans; D017589:Immunization Programs / Q000191:economics / Q000600:supply & distribution; D007223:Infant; D007231:Infant, Newborn; D007443:Intussusception / Q000209:etiology; D010343:Patient Admission; D012401:Rotavirus / Q000235:genetics; D012400:Rotavirus Infections / Q000191:economics / Q000453:epidemiology / Q000517:prevention & control*; D022243:Rotavirus Vaccines / Q000008:administration & dosage* / Q000009:adverse effects / Q000235:genetics; D014613:Vaccines, Attenuated / Q000008:administration & dosage / Q000009:adverse effects / Q000235:genetics
chemical_list: D022243:Rotavirus Vaccines; D014613:Vaccines, Attenuated